- $14.04m
- -$4.82m
- $0.01m
- 12
- 12
- 63
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.1 | ||
| Price to Tang. Book | 1.1 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,754.42 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -321.15% | ||
| Return on Equity | -102.63% | ||
| Operating Margin | -511875% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.55 | 1.75 | 1.18 | 3.37 | 0.01 | n/a | n/a | -67.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
Directors
- Peter Barrett NEC (68)
- Aoife Brennan PRE (45)
- Gregg Beloff CFO (53)
- Daniel Rosan FID
- Antoine Awad COO (41)
- Jamie Austin VPR
- Molly Harper OTH
- Caroline Kurtz OTH
- Michael Burgess IND (58)
- Michael Heffernan IND (56)
- Patricia Hurter IND (57)
- Lisa Kelly-Croswell IND (54)
- Nick Leschly IND (48)
- Edward Mathers IND (61)
- Richard Shea IND (69)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 20th, 2007
- Public Since
- September 30th, 2015
- No. of Shareholders
- 67
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 11,696,109
- Address
- PO Box 30, WINCHESTER, 01890
- Web
- https://www.synlogictx.com/
- Phone
- +1 6176592802
- Auditors
- KPMG LLP
Upcoming Events for SYBX
Q2 2025 Synlogic Inc Earnings Release
Similar to SYBX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Synlogic share price?
As of Today at 23:33 UTC, shares in Synlogic are trading at $1.20. This share price information is delayed by 15 minutes.
How has the Synlogic share price performed this year?
Shares in Synlogic last closed at $1.20 and the price had moved by -36.17% over the past 365 days. In terms of relative price strength the Synlogic share price has underperformed the S&P500 Index by -42.44% over the past year.
What are the analyst and broker recommendations for Synlogic?
The overall consensus recommendation for Synlogic is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Synlogic dividend yield?
Synlogic does not currently pay a dividend.
Does Synlogic pay a dividend?
Synlogic does not currently pay a dividend.
When does Synlogic next pay dividends?
Synlogic does not currently pay a dividend.
How do I buy Synlogic shares?
To buy shares in Synlogic you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Synlogic?
As of the previous close price of $1.20, shares in Synlogic had a market capitalisation of $14.04m.
Where are Synlogic shares listed?
Here are the trading details for Synlogic:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SYBX
What kind of share is Synlogic?
Based on an overall assessment of its quality, value and momentum Synlogic is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Synlogic share price forecast for 2025?
The analyst consensus target price for shares in Synlogic is $1.00. That is 16.67% below the last closing price of $1.20.
Analysts covering Synlogic currently have a consensus Earnings Per Share (EPS) forecast of -$0.47 for the next financial year.
Find out moreWhat is the trend in the Synlogic share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Synlogic. Over the past six months, its share price has underperformed the S&P500 Index by -17.43%.
As of the last closing price of $1.20, shares in Synlogic were trading -14.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Synlogic PE Ratio?
The Synlogic PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Synlogic?
Synlogic's management team is headed by:
- Peter Barrett - NEC
- Aoife Brennan - PRE
- Gregg Beloff - CFO
- Daniel Rosan - FID
- Antoine Awad - COO
- Jamie Austin - VPR
- Molly Harper - OTH
- Caroline Kurtz - OTH
- Michael Burgess - IND
- Michael Heffernan - IND
- Patricia Hurter - IND
- Lisa Kelly-Croswell - IND
- Nick Leschly - IND
- Edward Mathers - IND
- Richard Shea - IND